Skip to main content
. 2021 Sep 24;12:718032. doi: 10.3389/fneur.2021.718032

Table 2.

Baseline characteristics of 262 patients with spontaneous ICH in PSM cohort.

Clinical variables Total (n = 262) 3-month functional outcome 1-month mortality
Poor outcome Good outcome P-value Death Survival P-value
(n = 183) (n = 79) (n = 42) (n = 220)
Age (years) 58.77 ± 13.56 59.67 ± 13.42 56.67 ± 13.75 0.402 61.26 ± 14.82 58.29 ± 13.29 0.242
Male 177 (67.6) 124 (67.8) 53 (67.1) 0.915 28 (66.7) 149 (67.7) 0.893
GCS 13 (9, 15) 12 (8, 14) 15 (14, 15) <0.001 8 (6, 11) 14 (11, 15) <0.001
Admission SBP (mmHg) 167.17 ± 26.56 168.86 ± 27.25 163.24 ± 24.60 0.407 170.31 ± 27.05 166.57 ± 26.48 0.857
Admission DBP (mmHg) 97.56 ± 17.54 97.58 ± 17.86 97.49 ± 16.90 0.655 96.05 ± 18.81 97.85 ± 17.32 0.844
Duration from onset to hospitalization (h) 6 (4, 15) 6 (4, 12) 6 (4, 22) 0.242 5 (3, 8) 6 (4, 15) 0.015
History of hypertension 141 (53.8) 103 (56.3) 38 (48.1) 0.224 26 (61.9) 115 (52.3) 0.252
History of diabetes mellitus 14 (5.3) 13 (7.1) 1 (1.3) 0.054 1 (2.4) 13 (5.9) 0.352
Smoking 90 (34.4) 66 (36.1) 24 (30.4) 0.375 14 (33.3) 76 (34.5) 0.880
Alcohol abuse 88 (33.6) 67 (36.6) 21 (26.6) 0.115 13 (31.0) 75 (34.1) 0.694
Previous stroke 14 (5.3) 13 (7.1) 1 (1.3) 0.054 2 (4.8) 12 (5.5) 0.855
Antiplatelet or anticoagulation 21 (8.0) 13 (7.1) 8 (10.1) 0.409 3 (7.1) 18 (8.2) 0.821
Hematoma volume (ml) 20.10 (7.04, 35.15) 24.18 (9.61, 38.54) 10.13 (2.71, 24.02) <0.001 24.87 (8.88, 39.99) 18.29 (7.00, 33.09) 0.136
Hematoma location
    Supratentorial 215 (82.1) 160 (87.4) 55 (69.6) 0.001 34 (81.0) 181 (82.3) 0.838
    Infratentorial 47 (17.9) 23 (12.6) 24 (30.4) 8 (19.0) 39 (17.7)
Presence of IVH 38 (14.5) 32 (17.5) 6 (7.6) 0.037 9 (21.4) 29 (13.2) 0.165
Presence of hematoma expansion 61 (23.3) 47 (25.7) 14 (17.7) 0.163 14 (33.3) 47 (21.4) 0.093
Treatment
    Surgical intervention 61 (23.3) 53 (29.0) 8 (10.1) 0.001 10 (23.8) 51 (23.2) 0.930
    Conservative treatment 201 (76.7) 130 (71.0) 71 (89.9) 32 (76.2) 169 (76.8)
PLT (109/L) 148 (117, 196) 147 (116, 195) 153 (123, 187) 0.525 136 (112, 196) 153 (120, 196) 0.171
PT (s) 11.4 (10.9, 12.2) 11.4 (10.8, 12.3) 11.5 (11.0, 12.2) 0.651 11.6 (10.9, 12.3) 11.4 (10.9, 12.2) 0.703
APTT (s) 26.2 (23.5, 29.2) 25.9 (23.4, 28.9) 26.5 (23.9, 29.3) 0.650 24.8 (22.5, 29.8) 26.2 (23.6, 29.1) 0.511
INR 0.98 (0.93, 1.05) 0.98 (0.92, 1.05) 1.00 (0.96, 1.05) 0.169 0.99 (0.94, 1.10) 0.98 (0.93, 1.05) 0.421
Neutrophil (109/L) 8.36 (6.37, 10.81) 9.06 (6.80, 11.35) 7.50 (5.49, 9.08) <0.001 10.22 (7.19, 12.54) 8.19 (6.32, 10.39) 0.017
Lymphocyte (109/L) 1.05 (0.75, 1.49) 1.04 (0.71, 1.44) 1.13 (0.82, 1.57) 0.085 1.04 (0.70, 1.60) 1.06 (0.76, 1.48) 0.965
Monocyte (109/L) 0.38 (0.25, 0.49) 0.40 (0.28, 0.50) 0.34 (0.24, 0.46) 0.044 0.48 (0.40, 0.58) 0.36 (0.24, 0.47) <0.001
NLR 8.18 (4.88, 12.67) 8.94 (5.91, 13.26) 6.41 (4.05, 9.95) <0.001 10.31 (5.78, 14.86) 7.90 (4.87, 12.44) 0.271
SIRI 2.76 (1.63, 4.70) 2.99 (1.81, 5.20) 2.18 (1.30, 3.23) <0.001 4.60 (1.95, 8.47) 2.62 (1.63, 4.15) 0.003

Data are expressed as n (%), mean ± SD, or median (25th, 75th quartile).

ICH, intracerebral hemorrhage; PSM, propensity score matching; GCS, Glasgow Coma Scale; SBP, systolic blood pressure; DBP, diastolic blood pressure; IVH, intraventricular hematoma; PLT, platelet; PT, prothrombin time; APTT, activated partial thromboplastin time; INR, international normalized ratio; SIRI, systemic inflammation response index; NLR, neutrophil-to-lymphocyte ratio. Significant findings are expressed in bold and italic.